Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2

An Emergency Use Authorization was issued in the United States and in Europe for a monoclonal antibody monotherapy to prevent severe COVID-19 in high-risk patients. This study aimed to assess the risk of emergence of mutations following treatment with a single monoclonal antibody. Bamlanivimab was a...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Nathan Peiffer-Smadja, Antoine Bridier-Nahmias, Valentine Marie Ferré, Charlotte Charpentier, Mathilde Garé, Christophe Rioux, Aude Allemand, Philippa Lavallée, Jade Ghosn, Laura Kramer, Diane Descamps, Yazdan Yazdanpanah, Benoit Visseaux
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2021-08-01
coleção:	Viruses
Assuntos:	monoclonal antibodies SARS-CoV-2 COVID-19 variants resistance
Acesso em linha:	https://www.mdpi.com/1999-4915/13/8/1642
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!